ID   RMA-B7H6
AC   CVCL_VA23
SY   RMA/B7H6
DR   Wikidata; Q54950644
RX   PubMed=25830550;
RX   PubMed=29453518;
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:42400; NCR3LG1.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Transformant: ChEBI; CHEBI_23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC   Transformant: NCBI_TaxID; 11938; Rauscher murine leukemia virus (R-MuLV).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: T-cell; CL=CL_0000084.
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21604; Mouse leukemia
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_J385 ! RMA
CA   Cancer cell line
DT   Created: 14-05-18; Last updated: 10-04-25; Version: 8
//
RX   PubMed=25830550; DOI=10.1038/gt.2015.29; PMCID=PMC4529373;
RA   Wu M.-R., Zhang T., DeMars L.R., Sentman C.L.;
RT   "B7H6-specific chimeric antigen receptors lead to tumor elimination
RT   and host antitumor immunity.";
RL   Gene Ther. 22:675-684(2015).
//
RX   PubMed=29453518; DOI=10.1007/s00262-018-2124-1; PMCID=PMC11028385;
RA   Gacerez A.T., Hua C.K., Ackerman M.E., Sentman C.L.;
RT   "Chimeric antigen receptors with human scFvs preferentially induce T
RT   cell anti-tumor activity against tumors with high B7H6 expression.";
RL   Cancer Immunol. Immunother. 67:749-759(2018).
//